Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
University of Pittsburgh
University of Pittsburgh
Acepodia Biotech, Inc.
Fate Therapeutics
BGI, China
Ludwig Institute for Cancer Research
Incyte Corporation
Karolinska University Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HaEmek Medical Center, Israel
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
Immatics Biotechnologies GmbH